Nuvation Bio Inc. (NUVB): Price and Financial Metrics

Nuvation Bio Inc. (NUVB): $3.02

0.03 (+1.00%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add NUVB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#69 of 351

in industry

NUVB Price/Volume Stats

Current price $3.02 52-week high $4.16
Prev. close $2.99 52-week low $0.95
Day low $2.98 Volume 1,358,300
Day high $3.26 Avg. volume 1,247,190
50-day MA $3.02 Dividend yield N/A
200-day MA $1.98 Market Cap 746.46M

NUVB Stock Price Chart Interactive Chart >


Nuvation Bio Inc. (NUVB) Company Bio


Nuvation Bio Inc. operates as a bio-pharmaceutical company. The Company focuses on developing oncology medicines that will improve patient lives by addressing drug resistance. Nuvation Bio serves patients worldwide.


NUVB Latest News Stream


Event/Time News Detail
Loading, please wait...

NUVB Latest Social Stream


Loading social stream, please wait...

View Full NUVB Social Stream

Latest NUVB News From Around the Web

Below are the latest news stories about NUVATION BIO INC that investors may wish to consider to help them evaluate NUVB as an investment opportunity.

Companies Like Nuvation Bio (NYSE:NUVB) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 4, 2023

Nuvation Bio Announces Departure of Chief Financial Officer

NEW YORK, November 13, 2023--Nuvation Bio Inc. (NYSE: NUVB) (the "Company") announced today that Jennifer Fox will be stepping down from her role as Chief Financial Officer to pursue a new opportunity. Ms. Fox has advised the Company that she is seeking later stage development and commercial launch experience as part of her career development and that she is leaving with a high regard for the Company, its leadership and its financial state. Ms. Fox submitted her resignation on November 9, 2023 w

Yahoo | November 13, 2023

Nuvation Bio Inc (NUVB) Reports Q3 2023 Financial Results

Company's cash and marketable securities stand at $619.3 million as of Q3 2023, with a net loss of $19.6 million

Yahoo | November 2, 2023

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

NEW YORK, November 02, 2023--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2023, and provided a business update.

Yahoo | November 2, 2023

One Nuvation Bio Insider Raised Their Stake In The Previous Year

Insiders were net buyers of Nuvation Bio Inc.'s ( NYSE:NUVB ) stock during the past year. That is, insiders bought more...

Yahoo | October 23, 2023

Read More 'NUVB' Stories Here

NUVB Price Returns

1-mo -9.04%
3-mo 51.00%
6-mo 114.18%
1-year 71.59%
3-year -68.77%
5-year N/A
YTD 100.00%
2023 -21.35%
2022 -77.41%
2021 -27.35%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!